Nurix Therapeutics

1700 Owens Street
Suite 205
San Francisco
California
94158
United States

Tel: 415-660-5320

About Nurix Therapeutics

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

95 articles with Nurix Therapeutics

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 - March 20, 2023

3/20/2023

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479.
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

3/20/2023

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX-0479.
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

3/14/2023

Nurix Therapeutics, Inc. announced that preclinical data from its targeted protein degradation programs, NX-2127 and NX-5948, will be presented at the American Association for Cancer Research 2023 Annual Meeting, which is being held from April 14-19, 2023, in Orlando, FL.
Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

3/6/2023

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will provide a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14 at 10:40 a.m. ET.
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

2/9/2023

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fourth quarter and fiscal year ended November 30, 2022 and provided a corporate update.
Nurix Therapeutics to Participate in Upcoming February 2023 Investor Conferences

2/8/2023

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, and Gwenn M. Hansen, Ph.D., Nurix’s chief scientific officer, will participate in the following conferences in February.
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

1/9/2023

Nurix Therapeutics, Inc. today outlined key objectives and anticipated milestones for 2023 and provided an overview of recent progress in a presentation at the 41st Annual J.P. Morgan Healthcare Conference.
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

1/4/2023

Nurix Therapeutics, Inc. today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.
Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

12/15/2022

Nurix Therapeutics, Inc. announced that it has received clearance from the U.S. Food and Drug Administration for the company's Investigational New Drug application to expand the ongoing Phase 1 clinical program for NX-5948 into sites in the United States.
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

12/12/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today presented additional positive clinical data from its Phase 1 clinical trial of NX-2127 in two oral sessions by Anthony Mato, M.D., MSCE, former director of the Chronic Lymphocytic (CLL) Program at Memorial Sloan Kettering Cancer Center, and Omar Abdel-Wahab, M.D., Chair of Sloan Kettering Institute (SKI) Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center.
Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

12/7/2022

Nurix Therapeutics, Inc. announced that it will host a live webcast to review clinical data from the Phase 1 clinical trial of its leading BTK degrader program, NX-2127, at 8:30 pm CT on Monday, December 12, 2022.
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies

11/10/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented initial biomarker data demonstrating successful target engagement of CBL-B in its ongoing Phase 1 clinical trial with oral dosing of NX-1607.
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

11/10/2022

Nurix Therapeutics, Inc. presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, which is being held November 8 – 12th in Boston.
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

11/3/2022

Nurix Therapeutics, Inc. announced that its clinical-stage BTK degrader programs will be featured in two oral presentations and one poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held December 10-13, 2022 in New Orleans, LA.
Nurix Therapeutics to Participate in Upcoming November 2022 Investor Conferences

11/2/2022

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November:.
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

10/26/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced the presentation of new preliminary clinical data comprised of a case study of a patient with aggressive non-germinal center B-cell (non-GCB) diffuse large B cell lymphoma (DLBCL).
Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

10/19/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a Keynote Plenary presentation by Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, at the 5th Annual TPD Summit which is being held October 25‒28, 2022, in Boston, MA.
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

10/6/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2022 and provided a corporate update.
Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

10/5/2022

Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, announced six poster presentations at the upcoming Society for Immunotherapy of Cancer’s 37th Annual Meeting which is being held November 8 – 12th in Boston.
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

9/14/2022

Nurix Therapeutics, Inc. today announced the appointment of Edward C. Saltzman to its board of directors.

First
1
2
3
4
5
Next
Last